Congress moves to block insurers from cutting dialysis coverage

What it does

This bill amends Medicare law to strengthen protections for dialysis patients by prohibiting private health insurance plans from treating end-stage renal disease (ESRD) or dialysis services less favorably than other medical services. The bill clarifies that plans cannot single out dialysis for coverage limits or restrictions that disproportionately harm ESRD patients, though plans retain the right to choose which dialysis providers to include in their networks. The intent is to prevent private insurers from shifting the cost burden of dialysis care onto Medicare.

Why we flagged it

The bill's core function is to strengthen anti-discrimination protections for a specific patient population (ESRD/dialysis patients) against private insurers, using Medicare law as the enforcement mechanism. It is regulatory in nature, not a subsidy or appropriation.

What the text implies

• The bill may increase private insurers' costs by restricting their ability to limit dialysis coverage, potentially leading to higher premiums or reduced plan offerings in dialysis-heavy markets.
• Enforcement through Part 411 CFR (nonconformance determinations) delegates authority to HHS/CMS to define what constitutes 'disparate effect'—regulatory interpretation will determine the bill's actual scope.
• The carve-out preserving network-selection rights may create a loophole: plans could comply with the letter (equal coverage) while narrowing dialysis provider networks to reduce access or increase patient burden.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Dialysis patients gain explicit legal protection against insurance discrimination and cost-shifting, ensuring they receive equitable coverage. The bill preserves insurers' network-selection flexibility while closing a loophole that allowed plans to disfavor dialysis relative to other services, directly benefiting a vulnerable patient population.

Who stands to gain

• dialysis patients (reduced out-of-pocket costs, broader coverage)
• dialysis service providers (increased patient volume and insurance reimbursement)

Named in the bill

Medicare, ESRD (End-Stage Renal Disease) patients, Private health insurance plans, Dialysis providers, HHS/CMS (enforcement), Bristol Myers Squibb (BMY), Grifols (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

90 cosponsors: 46 Democrats, 44 Republicans.

• Mar 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 18, 2025 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

28 lobbying clients named this bill on 44 disclosure filings across 5 quarters, Jun 2025 to Jun 2026. Those filings disclosed $19,329,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

Mike Kelly, the sponsor, reported $955,974 in PAC receipts in the 2026 cycle. $10,500 of that came from 2 PACs tied to these lobbying clients.

• Lockheed Martin Corporation — $4,180,000 on 1 filing
• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• Boeing Company — $2,770,000 on 1 filing
• Fresenius Medical Care North America — $2,410,000 on 2 filings
• Service Employees International Union Ctw-clc — $1,355,000 on 5 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.